Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Oct 31, 2026 to Oct 31, 2027
  2. Study completion date: Oct 31, 2026 to Oct 31, 2027
  3. Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Publications: details revised at 3 of 3 entries
  4. Re-verified, no change to tracked fieldsv17
  5. Phase: Phase 3 to Phase 2
    • Results first posted: Nov 21, 2025
    • Primary endpoint revised
    • Secondary endpoints: 6 to 4
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. Primary completion date: Oct 31, 2023 to Oct 31, 2024v15
  2. Enrollment target: estimated 100 to confirmed 107
    • Primary completion date changed from estimate of Jul 10, 2024 to Oct 31, 2023
    • Study completion date: Jan 10, 2026 to Oct 31, 2026
    v14
  3. Re-verified, no change to tracked fieldsv13
  4. Primary completion date: Jan 10, 2024 to Jul 10, 2024v12
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v11
  6. Eligibility criteria expanded, about 26 wordsv10
  7. Eligibility criteria expanded, about 16 wordsv9
  8. Phase: Phase 2 to Phase 3v8
  9. Re-verified, no change to tracked fieldsv7
  10. Study completion date: Jan 31, 2026 to Jan 10, 2026v6
  11. Primary completion date: Dec 31, 2022 to Jan 10, 2024
    • Study completion date: Dec 31, 2024 to Jan 31, 2026
    • Start date: Jan 9, 2020 to Jan 10, 2020
    v5
  12. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 30, 2019 to Jan 9, 2020
    • Site details revised
    v4
  13. 2 versions Re-verified since Sep 9, 2019, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well software-aided imaging works in confirming tumor coverage with ablation (the removal or destruction of a body part or tissue or its function) on patients with liver tumors. The current standard for targeting tumor cells and evaluating the outcome of a liver ablation procedure is a visual inspection of the pre- and post-procedure computed tomography (CT) scans. Software-aided imaging systems, such as Morfeus, may help to improve the accuracy and effectiveness of liver ablation.
Trial Details
NCT Number NCT04083378
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Malignant Liver Neoplasm
Enrollment 107 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov